Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

batiraxcept (AVB-500)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

3DMed, Aravive, WuXi AppTec

Drug class:

AXL inhibitor, GAS6 inhibitor

Related drugs:

No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B	AVB-500 Sensitive: B - Late Trials AVB-500 Sensitive : B
GAS6 elevation	Ovarian Cancer	GAS6 elevation	Ovarian Cancer	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3
GAS6 overexpression	Ovarian Cancer	GAS6 overexpression	Ovarian Cancer	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3	olaparib + AVB-500 Resistant: C3 – Early Trials olaparib + AVB-500 Resistant : C3
AXL elevation + GAS6 elevation	Clear Cell Renal Cell Carcinoma	AXL elevation + GAS6 elevation	Clear Cell Renal Cell Carcinoma	cabozantinib tablet + AVB-500 Sensitive: C3 – Early Trials cabozantinib tablet + AVB-500 Sensitive : C3	cabozantinib tablet + AVB-500 Sensitive: C3 – Early Trials cabozantinib tablet + AVB-500 Sensitive : C3